• Cognizant Technology Solutions recently expanded its AI footprint by partnering with Travelport to embed Anthropic’s Claude into travel retail platforms and by launching agent-powered Electronic Prior Authorization APIs on its TriZetto Unify healthcare platform, extending AI deeper into both travel and U.S. healthcare workflows.
• By exposing TriZetto services as headless, agent-ready APIs aligned with HL7 FHIR standards and supporting the Model Context Protocol, Cognizant is positioning its platforms as core infrastructure for AI agents across multi-payer healthcare and large-scale travel transaction systems.
• We’ll now examine how Cognizant’s headless, agent-ready AI platforms in healthcare and travel reshape its existing investment narrative and outlook.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Cognizant Technology Solutions Investment Narrative Recap

To own Cognizant, you need to believe it can shift from labor-heavy IT services toward higher value AI platforms without eroding margins or revenue visibility. The latest Travelport and TriZetto AI announcements reinforce that pivot, but they do not remove the near term risk that AI automates work faster than Cognizant replaces it with platform and outcome-based deals, or that intense competition in AI consulting and services pressures pricing.

The TriZetto Electronic Prior Authorization launch is most relevant here, because it exposes Cognizant’s healthcare platform as headless, agent-ready APIs across multi-payer workflows. That aligns directly with the core catalyst that consensus analysts focus on: proprietary AI and agentic platforms that sit between models and systems of record, potentially supporting better pricing power and more recurring, IP-led revenue if client adoption of AI in healthcare operations continues to build.

Yet while AI platforms can support margins, investors should also be aware that rising fixed price exposure could backfire if...

Cognizant Technology Solutions' narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029. This requires 5.2% yearly revenue growth and a roughly $0.9 billion earnings increase from $2.2 billion today.

Uncover how Cognizant Technology Solutions' forecasts yield a $72.52 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected Cognizant to reach about US$26.0 billion in revenue and US$3.3 billion in earnings, and saw the AI builder push as expanding large fixed price and outcome work. The new Travelport and TriZetto agentic launches could either reinforce that upbeat view or highlight how much delivery and execution risk you are taking on, so it is worth comparing these bullish assumptions with your own expectations.

Explore 6 other fair value estimates on Cognizant Technology Solutions - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cognizant Technology Solutions research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Cognizant Technology Solutions research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cognizant Technology Solutions' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.